Cooley advised Calithera Biosciences on its $80.5 million shelf-takedown offering of 7,854,500 shares of common stock, which includes the full exercise of the underwriters’ option to…
Calithera Biosciences’ $80 Million Shelf-Takedown Offering
Cooley advised Calithera Biosciences on its $80.5 million shelf-takedown offering of 7,854,500 shares of common stock, which includes the full exercise of the underwriters’ option to…